Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic

Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic

Approximately 23% of metastatic castration-resistant prostate cancers (mCRPC) harbor deleterious aberrations in DNA repair genes. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) therapy has shown improvements in overall survival in patients with mCRPC who harbor somatic and/or germline altera...

Full description

Bibliographic Details
Main Authors: Alessia Cimadamore, Liang Cheng, Francesco Massari, Matteo Santoni, Laura Pepi, Carmine Franzese, Marina Scarpelli, Antonio Lopez-Beltran, Andrea Benedetto Galosi, Rodolfo Montironi
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Molecular Sciences
Subjects:
circulating tumor DNA
prostate cancer
metastatic castration-resistant prostate cancer
homology recombination repair genes
BRCA1
BRCA2
Online Access:https://www.mdpi.com/1422-0067/22/11/5522

Internet

https://www.mdpi.com/1422-0067/22/11/5522

Similar Items